In a double-blind, placebo-controlled trial involving menopausal women, when administered at a daily dose of 10mg for 12 weeks, S-equol significantly reduced the frequency of hot flashes by 58.7%. And the severity of neck or shoulder muscle stiffness also significantly decreased in the S-equol group. In contrast, women receiving a placebo only experienced a 34.5% reduction.

In a post-menopausal osteoarthritis mouse model, supplementation with S-equol can significantly reduce the OARSI (Osteoarthritis Research Society International) scores of mice knees with osteoarthritis of different severities. Experiments show that S-equol can slow down the progression of post-menopausal osteoarthritis by mitigating oxidative stress and the action of matrix-degrading enzymes involved in cartilage degradation.

Purkinje cells are the only neurons that emit efferent impulses from the cerebellar cortex, while astrocytes are the most widely distributed type of cells in the mammalian brain, supporting and separating nerve cells.Studies have shown that 1 and 10 nM treatment of S-equol promotes dendritic dendricity of Purkinje cells and proliferation of astrocytes,promoting cerebellar nerve health.

Meanwhile,after 24 h of treatment by 50 uM S-equol,it was found that S-equol could significantly inhibit LPS-induced iNOS expression with an inhibition rate of about 66%.

International journal of inflammation, 2018, 8496973.

· Equol exists in two chiral forms (R-equol and S-equol), but fecal bacteria only produce S-equol as the main metabolite of soy isoflavone. EquoYouth S-equol is produced by patented fermentation process.

· In terms of purity performance, EquoYouth S-equol has achieved over 99% ultra-high enantiomeric purity through its innovative patented process. This remarkable specification not only ensures the product's quality stability but also provides a strong guarantee for its biological activity, enabling the active ingredient to fully exert its physiological effects.